Celgene's MS drug ozanimod gets EU filing, with FDA submission to follow

The refuse-to-file letter added a year to ozanimod’s timeline, delaying the launch of a potential blockbuster with peak sales around $5 billion per year. (Celgene)

A year after the FDA issued Celgene a refuse-to-file letter for its multiple sclerosis drug ozanimod, the biotech is filing for regulatory approval in the European Union, with plans to refile in the U.S. this month. 

Celgene picked up ozanimod, an S1P receptor modulator, back in 2015, in its $7.2 billion acquisition of Receptos. It is seeking approval in the EU for relapsing-remitting multiple sclerosis (MS) and in the U.S. for relapsing forms of the disease.

Celgene had reckoned that a better safety profile than Novartis’ Gilenya—particularly with regard to "liver toxicities, QT prolongation and bradycardia”—boded well for the drug’s approval, but a substandard filing resulted in a refuse-to-file letter in February 2018. 

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

The FDA sent a letter after determining that the nonclinical and clinical pharmacology information Celgene provided were not up to snuff. The setback added a year to ozanimod’s timeline, delaying the launch of a potential blockbuster with peak sales around $5 billion per year. 

RELATED: After FDA rebuff, Celgene on track to refile ozanimod—in 2019

At the time, management explained that the letter was unrelated to potential concerns about S1P receptor modulators and said it thought it could use existing activities to address some of the agency’s feedback. But the incident also raised questions about Celgene’s credibility. 

“This just adds even more uncertainty and credibility questions, which is not helpful right now given Celgene is in a period where they need to instill confidence after the recent disappointments,” wrote Jefferies Analyst Michael Yee at the time. 

RELATED: 2 months after BMS megamerger, Celgene's JAK inhibitor to get priority review

In June 2018, Nadim Ahmed, Celgene’s president of haematology and oncology, pinned the blame for the filing on Receptos. He acknowledged that such refusal letters are rare for companies like Celgene and framed the dip in standards as a lesson in the need to integrate acquisitions. 

“[The FDA] kinda said ‘what happened guys, this isn’t what we usually expect from Celgene?’ And we had to say, you know, ‘mea culpa it’s on us’,” Ahmed said. “I think that 99% of folk at Celgene wouldn’t have submitted, but we had Receptos out on the West Coast and, for whatever reason, the decision was made to submit.”

Suggested Articles

Flagship Pioneering has raised $824 million for a fund to support biotech and health companies that have come up through its Flagship Labs foundry.

The FDA’s warning letters to breast implant manufacturers come during newly galvanized agency probes into the long-term safety of silicone implants.

At the annual meeting of the American College of Cardiology this week, a new analysis of Merck’s anacetrapib cast a shadow on DalCor’s hypothesis